Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 17/20 | 0.83 |
| ▸ | PTGER3 | P43115 | 17/20 | 0.83 |
| ▸ | PTGER4 | P35408 | 16/20 | 0.83 |
| ▸ | PTGER1 | P34995 | 9/20 | 0.83 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.46 |
| ▸ | PTGFR | P43088 | 2/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7804194 | 1.00 | PTGER2 (0.83) | PTGER2PTGER3PTGER4PTGER1CA1 | |
| SCHEMBL7805026 | 0.91 | PTGER2 (1.00) | PTGER2PTGER3PTGER4PTGER1CA1 | |
| SCHEMBL7805023 | 0.91 | PTGER2 (1.00) | PTGER2PTGER3PTGER4PTGER1CA1 | |
| SCHEMBL11830587 | 0.79 | PTGER3 (0.71) | PTGER2PTGER3PTGER4PTGER1CA1 | |
| SCHEMBL9658945 | 0.79 | PTGER3 (0.71) | PTGER2PTGER3PTGER4PTGER1CA1 | |
| SCHEMBL24075582 | 0.78 | PTGER4 (0.55) | PTGER2PTGER3PTGER4PTGER1KMT2A | |
| SCHEMBL7957261 | 0.77 | PTGER4 (0.76) | PTGER2PTGER3PTGER4PTGER1KMT2A | |
| SCHEMBL7957258 | 0.77 | PTGER4 (0.76) | PTGER2PTGER3PTGER4PTGER1KMT2A | |
| SCHEMBL7957266 | 0.75 | PTGER4 (0.70) | PTGER2PTGER3PTGER4PTGER1KMT2A | |
| SCHEMBL7966447 | 0.74 | PTGER3 (0.67) | PTGER2PTGER3PTGER4PTGER1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | MERCK FROSST CANADA & CO. | 2001-10-18 | — | — | US | disclosed |
| EP-1119542-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | Merck Frosst Canada & Co. (CA) | 2001-08-01 | — | — | EP | disclosed |
| US-6211197-B1 | CARBOXYLIC ACID OR TETRAZOLE DERIVATES; ANALGESICS, ANTIPYRETICS, AND ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | MERCK FROSST CANADA & CO. (CA) | 2001-04-03 | — | — | US | disclosed |
| WO-2000020371-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | MERCK FROSST CANADA & CO. (CA) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | PTGER1, PTGER2, PTGFR | PTGER2 2/4885PTGER3 9/4885PTGER4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.